Dr. Jonathan R. Whisenant, MD

Dr. Whisenant practices at Utah Cancer Specialists in Salt Lake City, Utah.

Dr. Whisenant's NPI, 1861441974, was assigned on May 8, 2006. Dr. Whisenant graduated from University of California, San Francisco School of Medicine in 1998. Dr. Whisenant holds Utah license 5948529-1205.

Dr. Whisenant's primary practice is Utah Cancer Specialists, at 1121 E 3900 S, Salt Lake City, UT 84124 in Salt Lake County. The practice phone is (801) 269-0231.

Dr. Whisenant's primary practice is Utah Cancer Specialists in Salt Lake City, Utah. Dr. Whisenant is also affiliated with St. Mark's Hospital. The medical group on file is Utah Cancer Specialists. Dmand AI also links Dr. Whisenant to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Whisenant practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Whisenant's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Whisenant is licensed in Utah.

CMS data shows 39,166 Medicare services from Dr. Whisenant across 45 procedure codes in 2024, for 306 Medicare patients. Medicare paid $601,825 for them. Every service was in an office.

CMS counts 306 Medicare patients who saw Dr. Whisenant in 2024. The largest group is 65 to 74, with 135 patients. 64% of them have high cholesterol, and 61% have high blood pressure. 8% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Whisenant's median patient age at 68, with 59% women.

In 2024, Dr. Whisenant wrote 577 Medicare Part D claims for 120 patients. 68% of them were for generic drugs. CMS names the drug for 353 of them, across 18 drugs with 11 or more claims each, at $1,621,079 in total drug cost. In 2023, CMS named 198 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Whisenant for performance year 2024, reported as part of a group. Dr. Whisenant accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Whisenant as offering telehealth.

Dmand AI links 16 papers to Dr. Whisenant, published from 2013 to 2025. 2018 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Bile Duct Neoplasms and Chemoradiotherapy. Dr. Whisenant has published most often in Am J Clin Oncol. Dr. Whisenant's most frequent co-authors are Ignacio Garrido-Laguna, MD, George M. Cannon, MD and Shane Lloyd, MD.

Dmand AI links Dr. Whisenant to 10 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Medullary, Colorectal Neoplasms, Hereditary Nonpolyposis and Gastrointestinal Stromal Tumors. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 65 general payments to Dr. Whisenant from 22 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 39% of the total. Exelixis Inc. paid the most, $6,410.

Dr. Whisenant graduated from University of California, San Francisco School of Medicine in 1998.